TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RESIGNATION OF NON-EXECUTIVE DIRECTOR

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Resignation of Independent Non-executive Director

The board of directors (the "**Board**") of TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") received a resignation letter dated March 31, 2026 from Ms. Zheng Zhelan (鄭哲蘭) ("**Ms. Zheng**"), an independent non-executive director of the Company. Ms. Zheng has decided to step down from her role as an independent non-executive director as well as the chairperson of the remuneration and appraisal committee of the Board (the "**Remuneration and Appraisal Committee**") and a member of each of the audit committee (the "**Audit Committee**") and the nomination committee (the "**Nomination Committee**") of the Board due to personal work arrangements.

The resignation of Ms. Zheng will take effect upon the election of a new independent non-executive director at the forthcoming annual general meeting of the Company, until which she will continue to perform her duties as an independent non-executive director, the chairperson of the Remuneration and Appraisal Committee and a member of each of the Audit Committee and the Nomination Committee.

Ms. Zheng has confirmed that she has no disagreement with the Board and that her decision to resign is based on her own work commitment and is not related to the Company. Further, the Board confirms that there are no other matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude to Ms. Zheng for her valuable contributions and support to the Company during her tenure.

Proposed Appointment of Independent Non-executive Director

Following the qualification review by the Nomination Committee, at the Board meeting convened on March 31, 2026, the Company considered and approved the Proposal of the appointment of Mr. Feng Weibo (馮維波) ("**Mr. Feng**") as an independent non-executive director and agreed to nominate Mr. Feng as the candidate for independent non-executive director, concurrently serving as the chairperson of the Remuneration and Appraisal Committee and a member of each of the Audit Committee and the Nomination Committee, with a term of three years commencing from the date of approval by the Company at the forthcoming annual general meeting.

Details of Mr. Feng's biography are set out below:

Mr. Feng, aged 62, is a level 4 staff member of Nanjing University (南京大學). From July 1985 to December 2023, Mr. Feng served successively as a teaching assistant, lecturer, associate professor, and researcher in education management at Nanjing University. He also successively served as the party secretary of the Communist Party of the Department of Physical Education at the School of Chemistry and Chemical Engineering, Jinling College, and the School of Education of Institute for International Education of Nanjing University before his retirement in January 2024. Mr. Feng has been an independent director of Nanjing Toua Hardware & Tools Co., Ltd. (南京騰亞精工科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301125), since July 2022. Mr. Feng obtained his bachelor's degree in Polymer Synthetic Materials from Nanjing University (南京大學) in July 1985.

Save as disclosed in this announcement, as at the date of this announcement, Mr. Feng confirmed (i) he has not held any other position within the Group and has not held any directorships in any other listed companies in Hong Kong or overseas in the last three years; (ii) he does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations required to be disclosed pursuant to Part XV of the SFO; (iii) he has no relationships with any other Directors, supervisors, members of senior management or substantial Shareholders; (iv) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (v) he has no past or present financial or other interest in the business of the Company or its subsidiary or any connection with any core connected person of the Company (as defined in the Listing Rules) under the Listing Rules as at the date of this announcement; and (vi) that there are no other factors that may affect his independence. The Board and the Nomination Committee of the Board are also of the view that Mr. Feng complies with the independence guidelines set out in Rule 3.13 of the Listing Rules.

Save as disclosed herein, there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

After Mr. Feng's appointment is approved by the shareholders' meeting, the Company will enter into a service contract with him. Mr. Feng will be entitled to a remuneration of RMB223,560 (before tax) per annum, which was determined by the Board after having considered, among other things, his responsibilities, authorities and benefits and the prevailing market level of companies of comparable size and similar operations. The remuneration of Mr. Feng is covered by his service contract.

The above proposal to appoint Mr. Feng as an independent non-executive director of the Company still needs to be submitted to the forthcoming Company's annual general meeting for approval.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board received a resignation letter dated March 31, 2026 from Dr. Yi Hua (易華) ("**Dr. Yi**"), a non-executive director of the Company. As a director delegated by the shareholders of the Company and considering the arrangement of relevant affairs of the shareholders he represents and his personal work arrangement, Dr. Yi has decided to step down from his role as a non-executive director. The resignation of Dr. Yi was to take effect immediately. Dr. Yi has confirmed that he has no disagreement with the Board and that his decision to resign is based on his own work commitment and is not related to the Company. Further, the Board confirms that there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its sincere gratitude to Dr. Yi for his valuable contributions and support to the Company during his tenure.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, March 31, 2026

As at the date of this announcement, the Board comprises (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.